Nutrabiotix LLC, spun out from research done at Purdue University, is involved in the development and commercialization of a market-ready, targeted function fiber product designed to help people affected by Irritable Bowel Syndrome (IBS) and promote overall gastrointestinal health. The firm has developed a designer fiber that addresses the problem of dietary fiber intolerance which is caused by the rapid fermentation that occurs when bacteria extract energy from fiber. Nearly everyone is affected by intolerance, depending on the amount of fiber they digest and how rapidly it ferments. The fiber can be designed to target different locations in order to enable the bacteria in the large intestine to receive important nutrients from the fiber and promote overall health. Intended features include digestion without bloating, targeted delivery of digestive health through extended fermentation, high butyrate and prebiotic effects, and potential prevention of intestinal and system disorders and diseases. The fiber does not cause typical side effects associated with commercially available fermentable fiber products such as uncomfortable bloating. Other products in the companys research pipeline will address treating certain disease states that are linked to poor digestive health, such as IBD; preventing colon polyps and cancer; managing obesity and associated disorders like diabetes and coronary disease; preventing C. Difficile diarrhea - the most common cause of diarrhea in hospital patients; and improving the disease course of certain viral diseases like HIV through preventing activation of systemic inflammatory processes by limiting gut leakiness to bacterial products like endotoxin. Nutrabiotix's technology is patented and exlusively controlled by the company
